BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

MabThera regulatory update

Roche disclosed in its 4Q10 earnings that it submitted an sBLA to FDA for rituximab to treat antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rituximab is already approved in the U.S....

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >